Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries  by Gårdsvoll, Henrik et al.
Selection of peptides that bind to plasminogen activator inhibitor 1
(PAI-1) using random peptide phage-display libraries
Henrik Gaîrdsvolla;b;*, Anton-Jan van Zonnevelda, Arne Holmc, Eric Elderinga,
Marja van Meijera, Keld DanÖb, Hans Pannekoeka
aDepartment of Biochemistry, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
bThe Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, DK-2100 Copenhagen, Denmark
cChemical Department, Royal Veterinary and Agricultural University, Thorvaldvej 40, DK-1871 Copenhagen, Denmark
Received 2 June 1998
Abstract Large random hexa- and decapenta-peptide libraries
were constructed and displayed on the surface of the filamentous
phagemid pComb8. Panning of the hexa-peptide library on
immobilized plasminogen activator inhibitor 1 (PAI-1) specifi-
cally selected a minor fraction of concatemers, indicating that
binding to PAI-1 requires an extended amino acid sequence.
Accordingly, the decapenta-peptide library exclusively yielded
PAI-1 binding peptides of 15 amino acid residues. None of these
phage-bound peptides prevented the interaction between PAI-1
and its target serine protease urokinase (u-PA). To isolate
peptides that block the interaction between PAI-1 and u-PA,
phages bound to immobilized PAI-1 were eluted by incubation
with u-PA. Remarkably, this procedure resulted in elution of a
unique phage type that harbors a concatemer of decapentamers,
consisting of 49 amino acid residues with no obvious similarity to
the primary sequence of PAI-1 or u-PA.
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1. Introduction
Plasminogen activator inhibitor 1 (PAI-1) is a major regu-
latory protein of ¢brinolysis and possibly of other processes,
including the degradation of extracellular matrices during can-
cer invasion [1,2]. Tissue-type (t-PA) and urokinase-type plas-
minogen activator (u-PA) are the initiators of these processes
and the activity of these activators is rapidly neutralized upon
complex formation with PAI-1. PAI-1 belongs to the serine
protease inhibitor (‘serpin’) superfamily of homologous pro-
teins (reviewed in [3]). It acts as a pseudo-substrate by mim-
icking the genuine substrate plasminogen. To that end, the
inhibitor presents its reactive center P1 residue (arginine
346) to form a stable acyl-enzyme intermediate, ultimately
leading to cleavage of the peptide bond [4,5].
Clinical studies and observations with transgenic mice have
provided conclusive evidence for the in vivo regulatory func-
tion of PAI-1 in ¢brinolysis and thrombolysis. Homozygous
individuals with complete PAI-1 de¢ciency su¡er from an
increased bleeding tendency [6,7], whereas so-called PAI-1
knock-out mice display a greater resistance to venous throm-
bosis due to increased ¢brinolysis [8]. On the other hand, mice
overexpressing PAI-1 develop venous occlusions, conceivably
as a result of decreased ¢brinolysis [9]. In humans, high levels
of PAI-1 have been associated with an increased risk for my-
ocardial reinfarction and thrombosis [10]. These observations
might be explained by the occurrence of platelet-rich thrombi,
containing high levels of ¢brin-bound PAI-1 [11,12]. Accord-
ingly, the application of either inhibitory anti-PAI-1 antibod-
ies or low-molecular-weight compounds either in a rabbit jug-
ular vein model or in a canine coronary artery model for
thrombosis and stenosis enhanced t-PA-mediated thrombosis
and reduced the frequency of reocclusions [13^15].
In contrast to the well-de¢ned role of PAI-1 in ¢brinolysis,
the mechanism of action of the inhibitor in metastasis has not
been documented to the same extent. However, it has been
reported that high levels of PAI-1 are found to be associated
with a variety of cancers. PAI-1 is speci¢cally localized to the
tumor stroma and, in many cases, to areas surrounding the
tumor vessels (reviewed in [16]). These observations may sig-
nify that high levels of PAI-1 would prevent the degradation
of tumor tissue by u-PA-induced proteolysis of extracellular
matrices [17]. Consequently, it is hypothesized that inhibition
of PAI-1 activity under these circumstances may induce auto-
degradation of the tumor tissue [18]. These considerations on
the function of PAI-1 in ¢brinolysis and thrombolysis and its
potential role in cancer led us to develop low-molecular-
weight compounds to ultimately inhibit the activity of PAI-1
in vivo under a variety of pathological conditions. In this
report, we constructed and analyzed random hexa- and deca-
penta-peptide libraries that are displayed on the surface of
¢lamentous phages (reviewed in [19]) to search for PAI-1
binding peptides. Such peptides may be instrumental for fu-
ture studies to delineate in detail the interaction between PAI-
1 and other components, notably the serine proteases u-PA,
t-PA and thrombin and the accessory factors vitronectin, hep-
arin and ¢brin [1]. Finally, these peptides may serve as lead
compounds for a rational design of low-molecular-weight
products to combat thrombotic complications and possibly
tumorigenesis.
2. Materials and methods
2.1. Reagents
Fully active human recombinant PAI-1 was a generous gift from
Dr. T.M. Reilly (DuPont Merck Pharmaceutical Comp., Wilmington,
DE, USA). Human u-PA was purchased from Serono (Aubonne,
France). The phage-display vectors pComb8 and pJuFo were gifts
from Dr. C.F. Barbas (The Scripps Research Institute, La Jolla,
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CA, USA) and Dr. M. Suter (University of Zurich, Biochemical In-
stitute, Zurich, Switzerland), respectively.
2.2. Construction of a phage displaying the somatomedin B domain of
vitronectin
To establish conditions for a speci¢c interaction between immobi-
lized PAI-1 and phage-displayed peptides, a phagemid was con-
structed that displays the high a⁄nity PAI-1 binding site of vitronec-
tin, i.e. the somatomedin B (SMB) domain [20]. The cDNA encoding
this domain was inserted by overlap PCR into XbaI- and KpnI-di-
gested pJuFo DNA [21], a vector derived from the pComb series of
phagemids [22]. To that end, the following primers were used, based
on the vitronectin cDNA sequence (EMBL accession number
X03168): forward 5P-AGATCTAGAGACCAAGAGTCATGCAAG
(XbaI site underlined) and reverse 5P-ACCGGTACCTTACATAGT-
GAACACATCCCC (KpnI site underlined). The resulting phagemid
was denoted pJuFo/SMB.
2.3. Construction of phage-displayed random peptide libraries
Peptide libraries were constructed by using the multivalent phage-
display vector pComb8 that had been originally developed to express
the Fab part of immunoglobulins on the phage surface [22]. Hexa-
and decapenta-peptides (LE(X6)TS or LE(X15)TS) are expressed as
fusion proteins, preceded by a penta-peptide (AQVKL) represent-
ing a consensus of the ‘fairly constant region’ (FR1) of murine im-
munoglobulin heavy chains, and followed by the major phage coat
protein VIII (gp8). The dipeptides LE and TS are encoded by sequen-
ces corresponding to restriction sites for XhoI and SpeI that are used
to insert random oligonucleotides (18-mer or 45-mer, respectively)
into pComb8. Double-stranded DNA inserts, encoding randomized
hexa- and decapenta-peptides were prepared as follows. Oligo-
nucleotides 5P-GTGCAGCTCGAG(NNN)6ACTAGTGGTGGCGG-
TGGC-3P and 5P-GTGCAGCTCGAG(NNS)15ACTAGTGGTGG-
CGGTGGC-3P and primer 5P-GCCACCGCCACCACTAGT-3P
(N = A, T, G or C and S = G or C) were made by automated DNA
synthesis. Complementary DNA strands were made after annealing of
the respective oligonucleotide with the primer, followed by incubation
with Sequenase 2.0 (USB, Cleveland, OH, USA) in the presence of
dNTPs. Double-stranded DNA was inserted into pComb8 after diges-
tion with XhoI and SpeI. High e⁄ciency transformation of Escherichia
coli strain XL1-Blue (Stratagene, La Jolla, CA, USA) was done by
electroporation. After transformation, SOC medium was added and
the cultures were shaken at 220 rpm for 1 h at 37‡C. Then, aliquots
were taken and serial dilutions were plated on LB agar plates, con-
taining ampicillin and tetracycline, to determine the library size
(2.8U108 and 1.6U107 for the hexa- and decapenta-peptide library,
respectively). Determination of the frequency of inserts of the two
libraries was done by DNA sequencing of several independent clones.
Ten out of 10 clones of the hexa-peptide library were found to contain
the expected insert of 18 random bp and nine out of 10 clones of
decapenta-peptide library contains the expected 45 random bp insert,
whereas one clone did not contain an insert. Hence, the percentage of
inserts in the hexa- and decapenta-peptide libraries approaches 100%
and will be about 90%, respectively. Finally, phage libraries were
made by infection of transformed E. coli XL1-Blue cells with
VCSM13 helper phage (Stratagene).
2.4. Panning of peptide libraries displayed on phages
Selection of PAI-1 binding phages was performed in a biopanning
assay. Brie£y, 0.5 Wg of PAI-1 in 0.1 sodium bicarbonate (pH 8.6) was
coated for 16 h at 4‡C onto wells of microtiter plates (Costar, Cam-
bridge, MA, USA). Wells were blocked for 1 h at 37‡C with TBS, 3%
(w/v) bovine serum albumin (BSA). Then, approximately 1010 phages
in TBS containing 1% BSA (w/v) were incubated for 1 h at room
temperature in BSA-coated wells. Subsequently, non-bound phages
were transferred to PAI-1-coated wells (‘panning’). After incubation
for 2 h at room temperature, the wells were extensively washed with
TBS, 0.5% (v/v) Tween-20. Phages that bind to immobilized PAI-1
were recovered by adding exponentially growing E. coli XL1-Blue
cells to the wells to allow infection and ampli¢cation of phages. The
procedure for panning, washing and ampli¢cation was repeated three
times. As indicated for a particular experiment, the elution of phages
that bind to immobilized PAI-1 was done for 1 h at room temperature
by adding 5 Wg/well of u-PA. The procedure for panning, washing,
elution with u-PA and ampli¢cation was repeated three times.
2.5. Screening of phage binding to PAI-1 by phage sandwich ELISA
Whole phage populations or small-scale phage preparations, ob-
tained from single colonies of the subsequent rounds of a⁄nity selec-
tion, were analyzed for binding to PAI-1 by phage sandwich ELISA.
Brie£y, 5U109 phages in TBS, 1% (w/v) BSA were incubated for 2 h
at room temperature in PAI-1- or BSA-coated wells. For competition
experiments, preincubation of immobilized PAI-1 with synthetic pep-
tides, dissolved in TBS containing 1% (w/v) BSA, or with u-PA (con-
trol glu-plasminogen) was performed for 15 or 30 min, respectively.
Phages bound to immobilized PAI-1 and to immobilized BSA were
detected by incubation with polyclonal anti-M13 biotin conjugate (5
PrimeC3 Prime, Inc., SanverTech, Heerhugowaard, The Nether-
lands), followed by incubation with horseradish peroxidase-coupled
streptavidin and staining.
2.6. Peptide synthesis
The phage-derived peptide LLLWPLSEKPVVLPE and a control
peptide AGEELTSFMQWAVLK were made by solid-phase synthe-
sis, using Fmoc chemistry. The peptides were puri¢ed by gel ¢ltration
and the products were found to be more than 90% pure, according to
HPLC analysis. The identity was veri¢ed by MALDI-TOF MS.
3. Results and discussion
3.1. Selection of PAI-1 binding phages from a random
hexa-peptide library
First, conditions were established for speci¢c binding (pan-
ning), washing and elution of phage-displayed peptides to
immobilized PAI-1. For that purpose, a control phage was
constructed that displays the SMB domain of vitronectin on
its surface in a biologically active con¢guration [20]. The SMB
domain constitutes the high-a⁄nity interaction site that exclu-
sively binds to active PAI-1, while no binding occurs to latent
or inactivated PAI-1. The speci¢city of the binding of the
SMB domain to PAI-1 is illustrated by the following obser-
vation. pJuFo/SMB phages were mixed with a 100 000-fold
excess of the parental pJuFo phages, devoid of the SMB do-
main. After three rounds of panning with immobilized PAI-1,
washing, elution and ampli¢cation, PCR was performed on 10
colonies using the primers outlined before. Nine out of 10
colonies contained the SMB cDNA insert, indicating an en-
richment factor of about 105, demonstrating the speci¢city of
the procedure. Subsequently, a phage-displayed random hexa-
peptide library, consisting of 2.8U108 independent clones,
was constructed and used for the selection of PAI-1 binding
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Table 1
PAI-1 binding peptides selected from random hexa-peptide library
Amino acid sequence insert Number of clones
GQFWHLTSMSGSYFLEPFDLISTSQQRNIPLEIRDADT 17/22
WLLGQDTSGVLWAELESIEGLS 2/22
WWLSHVTSTFEFQTLETLSDWS 2/22
LDWGQWTSLILSRHLEQLALIV 1/22
The underlined sequences indicate amino acids encoded by DNA sequences corresponding to restriction sites for XhoI (LE) and SpeI (TS) that have
been used to insert 18 random bp into pComb8. Tryptophan (W) residues are indicated in bold.
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peptides. It should be noted that sequence analysis had shown
that approximately 100% of the clones harbor the expected
insert of 18 bp. After four rounds of panning, washing and
elution, using identical conditions as for the binding of pJuFo/
SMB phages to PAI-1, individual clones were ampli¢ed and
serial dilutions of phage stocks were assayed, using the phage
sandwich ELISA with either immobilized PAI-1 or immobi-
lized BSA. Twenty-two phages that displayed binding to PAI-
1, but not to BSA, were sequenced (Table 1). Remarkably,
each of the phages contains a concatemer, encoding three or
¢ve copies of in-frame hexa-peptides. Notably, four di¡erent
phage types were encountered: (i) 17 out of 22 contain the
same insert, encoding 38 amino acid residues, (ii) two, two
and one out of 22 harbor an insert, encoding 22 amino acid
residues. The amino acid sequences of these four di¡erent
phage types do not reveal an obvious consensus, except for
an apparent enrichment of tryptophan residues in the amino-
terminal half of these peptides, in accordance with data of
others (summarized in [19]). These ¢ndings are in contrast
to other observations with our random hexa-peptide library.
In that case, the library was employed to map the epitope of a
monoclonal antibody (EF1-4), directed against elastase-de-
graded human ¢brinogen. These experiments yielded exclu-
sively hexa-peptides carrying phages with a clear consensus
sequence (H. Gaîrdsvoll, R. Bos and H. Pannekoek, unpub-
lished data). As mentioned before, a limited analysis of the
library revealed exclusively inserts that encode six contiguous
amino acid residues. Nonetheless, the current procedure to
isolate PAI-1 binding phages speci¢cally selects a fraction of
phages that is present at a low frequency in the library. This
conclusion supports the assumption that the structural and/or
conformational requirements for a ligand to bind to PAI-1
extend beyond those comprised in a hexa-peptide.
3.2. Selection of PAI-1 binding phages from a random
decapenta-peptide library
In view of the ¢ndings above, we constructed a phage-dis-
played, random decapenta-peptide library. This library con-
sists of 1.6U107 independent clones of which approximately
90% contain a single insert of 45 bp, whereas about 10% of
the clones do not harbor an insert. Again, selection of phages
was performed using immobilized PAI-1. All of the clones
recovered from the ¢nal round of selection contain inserts
encoding a decapenta-peptide (Table 2). The inserts of 17
independent clones were sequenced: four out of 17 appeared
to have an identical sequence (#1) as well as two others (#13).
An alignment of 10 di¡erent sequences (#1^10), using a multi-
ple alignment program (MAP) [23], revealed a moderate con-
sensus sequence, namely LLlWPg^lsd/e^PVvLP, which may
indicate that these peptides bind to the same site on PAI-1.
Consequently, the remaining peptides (#11^13) may bind to
di¡erent sites on PAI-1. Furthermore, an evident enrichment
is observed for the occurrence of tryptophan (W) residues as
noted before (see Table 1 and [19]). To con¢rm the speci¢city
of the selected peptides and to exclude that binding of the
peptides to PAI-1 is only observed in the context of a fusion
protein, a soluble peptide corresponding to the most fre-
quently encountered sequence (LLLWPLSEKPVVLPE) was
synthesized. Indeed, binding of the corresponding decapen-
ta-peptide-carrying phages to immobilized PAI-1 was inhib-
ited in a dose-dependent manner by this particular synthetic
peptide, whereas no inhibition was observed with a control
peptide (Fig. 1). Subsequently, we assessed whether the bind-
ing of the LLLWPLSEKPVVLPE-containing phage to PAI-1,
as well as the other phages mentioned in Table 2, would
interfere with the interaction between PAI-1 and u-PA. How-
ever, in none of the cases we found that the addition of u-PA
prevented the binding of the phages to PAI-1 (results not
shown). Although the recovered decapenta-peptide phages
may be instrumental in the analysis of the interaction between
PAI-1 and other components, in this study we primarily fo-
cused on the identi¢cation of peptides that prevent the bind-
ing of u-PA to PAI-1.
3.3. Selection of a peptide that prevents PAI-1/u-PA interaction
For the aim outlined above, we developed a speci¢c com-
petition elution procedure to isolate peptides that share a
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Fig. 1. Competition between phage-bound and soluble peptide
LLLWPLSEKPVVLPE for binding to PAI-1. 5U109 pComb8/
LLLWPLSEKPVVLPE phages were preincubated with the indicated
concentrations of the soluble LLLWPLSEKPVVLPE decapenta-pep-
tide or a control decapenta-peptide as outlined in Section 2. Subse-
quent binding of phages to immobilized PAI-1 was monitored by
the administration of a polyclonal anti-M13 biotin conjugate, fol-
lowed by incubation with horseradish peroxidase-coupled strepavi-
din. The experiments were performed in duplicate.
Table 2
PAI-1 binding peptides selected from random decapenta-peptide li-
brary
No. Amino acid sequence insert Number of clones
1 LLLWPLSEKPVVLPE 4/17
2 LLGWMGLVEHDWLPL 1/17
3 SLWSLVLGPESILGP 1/17
4 LLWGRAVDLQESLVV 1/17
5 WLGMPMRDYSPVLLP 1/17
6 WLWPAESLVSVPYMV 1/17
7 WLELMSTRADPTLPL 1/17
8 WFGVAGGWDLGPQLG 1/17
9 WFMGREEVVGMSLVP 1/17
10 WIMLDWPGRLSDIPV 1/17
11 YLMFLDMLDPEQSVL 1/17
12 MLGLVAPRPLLQEVV 1/17
13 CILFLRCGDIQLVTP 2/17
Homology searches were performed using the multiple alignment pro-
gram (MAP; [19]), comparing the amino acid sequences of clones 1^
10. These inserts share a moderate consensus sequence, i.e. LLlWPg^
lsd/e^PVvLP (capital letters signify high probability, whereas lower-
case letters correspond to lower probability). Tryptophan residues are
indicated in bold.
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PAI-1 binding site with u-PA. To that end, we employed the
random decapenta-peptide library that was bound to immo-
bilized PAI-1, extensively washed and then incubated with 5
Wg/well of u-PA. This procedure of panning, washing, elution
with u-PA and, ¢nally, ampli¢cation of the eluted phages was
repeated three times. Subsequently, the inserts of 12 independ-
ent clones were sequenced. Surprisingly, only a single unique
sequence was encountered that consists of a concatemer of
inserts, encoding a peptide of 49 amino acid residues (Table
3). In contrast to the previous experiments (Tables 1 and 2),
the 49 amino acid long peptide is devoid of tryptophan resi-
dues, however, we observed an obvious enrichment for proline
(P) and histidine (H) residues. Furthermore, alignment of the
49 amino acid sequence with that of u-PA did not reveal a
common sequence or motif. Again, it should be noted that a
limited sequence analysis of the original decapenta-peptide
library revealed only single inserts of 45 bp, indicating that
concatemers constitute only a minor fraction of the library.
However, as a consequence of the chosen selection procedure,
a rare peptide-harboring phage is speci¢cally recovered. At-
tempts to chemically synthesize a complete, soluble peptide of
49 amino acids, and truncated versions of it, have not been
successful as yet and, in view of the extreme length, might
present a considerable hurdle. Finally, we veri¢ed the specif-
icity of the 49 amino acid peptide in the interaction between
PAI-1 and u-PA. For that purpose, we performed a competi-
tion experiment with u-PA or with glu-plasminogen, a protein
with a similar structure and amino acid composition. Our
data demonstrate that u-PA inhibits the binding of the 49
amino acids carrying phage to PAI-1 in a dose-dependent
manner, whereas glu-plasminogen did not (Fig. 2). A rational
explanation for these ¢ndings is that the peptide and u-PA
share (part of) a binding site on PAI-1, although at this point
it cannot be excluded that complex formation between PAI-1
and u-PA induces a conformational change that subsequently
prevents binding of the peptide. Future studies with a soluble
preparation of the peptide should reveal whether it acts as a
competitive or a non-competitive inhibitor.
Finally, it should be noted that none of the PAI-1 binding
peptides and concatemers, selected from the hexamer and the
decapentamer libraries, has an amino acid sequence with ob-
vious homology to the ‘linear’ sequence of either PAI-1 or u-
PA. Similar ¢ndings have been reported for peptides that
interfere with other protein-protein interactions. For example,
phage-displayed peptides have been isolated that block the
interaction between the urokinase receptor and u-PA [24].
Similarly, these peptides reveal no homology with the amino
acid sequence of these components. However, it cannot be
excluded that the three-dimensional structure of these proteins
encompasses quasi-linear arrays of amino acids that may be
homologous to the selected peptides. In conclusion, by using
phage display of random peptide libraries, we identi¢ed novel
peptides that bind to PAI-1. These peptides may constitute
useful tools for further studies on the interaction between
PAI-1 and its various protein targets. In particular, we have
designed a competitive elution protocol to enrich for peptides
that interfere with the interaction between PAI-1 and u-PA. A
single concatemer was identi¢ed, consisting of 49 amino acid
residues, that may serve as starting point for shorter versions
that will be assessed in experimental models that rely on u-PA
activity.
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